This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NuVasive's (NUVA) Global Prospects Solid, Competition Rife
by Zacks Equity Research
NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.
Winning Stock Picks from the Top 5 Industries with the Biggest Job Growth
by Kevin Matras
Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include BKE, MTZ, SSTI, ODFL and SYK.
The Zacks Analyst Blog Highlights: 3M, Altria, Stryker, UnitedHealth and Veeva
by Zacks Equity Research
The Zacks Analyst Blog Highlights: 3M, Altria, Stryker, UnitedHealth and Veeva
Top Stock Reports for 3M, Altria & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including 3M (MMM), Altria (MO) and Stryker (SYK).
Why Is Stryker (SYK) Up 4.1% Since Its Last Earnings Report?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured expert Kevin Matras highlights: Waste Connections, Roper, Stryker and Hi-Crush
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Waste Connections, Roper, Stryker and Hi-Crush
Winning Stock Picks from the Top 4 Industries with the Biggest Job Growth
by Kevin Matras
Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include WCN, ROP, SYK and HCLP.
Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.
Medical Product Stock Earnings Roster for Apr 26: BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.
Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) might repeat its gain streak in CAG for Q1, earlier driven by strong double-digit growth in reference labs and consumables plus a high-single-digit rise in rapid assay sales.
Can Higher System Sales Drive Cerner's (CERN) Q1 Earnings?
by Zacks Equity Research
Cerner's (CERN) Q1 earnings likely to reflect strength in System Sales and lucrative EHR prospects.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) Pharmaceutical business likely to put up a soft performance in Q3; raised guidance buoys optimism.
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) likely to gain from core BD Medical segment and strategic buyouts.
Can Hologic (HOLX) Diagnostics Growth Recur in Q2 Earnings?
by Zacks Equity Research
A strong Panther system and an increasing utilization of Aptima women's health assays add stimulus to Global growth within Hologic's (HOLX) molecular diagnostics.
Here's Why You Should Invest in Stryker (SYK) Right Now
by Zacks Equity Research
Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.
Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings?
by Zacks Equity Research
Pacific Biosciences gains ground on solid Sequel Growth, while shrinking service revenues raise concern.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q1 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) gains from EUROIMMUN buyout, solid guidance buoys optimism.
4 MedTech Stocks to Keep in Good Books This Earnings Season
by Zacks Equity Research
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
by Zacks Equity Research
Stryker's (SYK) Neurotech business goes strong, VEXIM buyout likely to boost segment.
Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?
by Zacks Equity Research
Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.
Stryker Loses 7.6% in a Month: What's Weighing It Down?
by Zacks Equity Research
Stryker's (SYK) declining margins and demand for healthcare products raise concern.
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Stryker Closes Entellus Buyout, Bolsters Neurotechnology Line
by Zacks Equity Research
Stryker (SYK) maintains its acquisition-driven strategy to provide superior and more economic patient experiences.
Stryker (SYK) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.